Tvardi Therapeutics, Inc. financial data

Symbol
CARA on Nasdaq
Industry
Pharmaceutical Preparations
Location
3 Sugar Creek Ctr. Blvd., Ste 525, Sugar Land, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
Cara Therapeutics, Inc. (to 4/11/2025), Cara Therapeutics Inc (to 7/21/2010)
Latest financial report
10-K - Q4 2024 - Mar 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 551 % +3.05%
Quick Ratio 13.7 % -4.38%
Debt-to-equity 587 %
Return On Equity -756 % -519%
Return On Assets -110 % -22.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.57M shares -91.6%
Common Stock, Shares, Outstanding 4.57M shares +0.69%
Entity Public Float 12.1M USD -90.7%
Common Stock, Value, Issued 5K USD 0%
Weighted Average Number of Shares Outstanding, Basic 4.56M shares +1.12%
Weighted Average Number of Shares Outstanding, Diluted 4.56M shares +1.12%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 7.14M USD -66%
Research and Development Expense 32.8M USD -69.8%
General and Administrative Expense 26.5M USD -4.5%
Operating Income (Loss) -58.4M USD +51.9%
Income Tax Expense (Benefit) -398K USD
Net Income (Loss) Attributable to Parent -70.9M USD +40.2%
Earnings Per Share, Basic -15.5 USD/shares +40.9%
Earnings Per Share, Diluted -15.5 USD/shares +40.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.9M USD -26.8%
Cash, Cash Equivalents, and Short-term Investments 37.9M USD -62.4%
Accounts Receivable, after Allowance for Credit Loss, Current 407K USD -85.3%
Inventory, Net 900K USD -68.1%
Assets, Current 43.8M USD -62.3%
Property, Plant and Equipment, Net 3.42M USD +148%
Operating Lease, Right-of-Use Asset 3.65M USD +360%
Assets 43.8M USD -65.2%
Accounts Payable, Current 1.43M USD -87.6%
Liabilities, Current 3.97M USD -84.5%
Operating Lease, Liability, Noncurrent 7.32M USD
Liabilities 48.4M USD -29.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -25K USD +94.3%
Retained Earnings (Accumulated Deficit) -756M USD -10.3%
Stockholders' Equity Attributable to Parent -4.59M USD -108%
Liabilities and Equity 43.8M USD -65.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.5M USD +12%
Net Cash Provided by (Used in) Financing Activities -685K USD -222%
Net Cash Provided by (Used in) Investing Activities 26M USD +46.6%
Common Stock, Shares Authorized 16.7M shares +100%
Common Stock, Shares, Issued 4.57M shares +0.69%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 37.9M USD -29.4%
Deferred Tax Assets, Valuation Allowance 201M USD +4.08%
Deferred Tax Assets, Gross 201M USD +3.38%
Operating Lease, Liability 7.49M USD +663%
Payments to Acquire Property, Plant, and Equipment 836K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -70.6M USD +39.7%
Lessee, Operating Lease, Liability, to be Paid 14.4M USD +1334%
Property, Plant and Equipment, Gross 4.99M USD +172%
Operating Lease, Liability, Current 3.42M USD +588%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.33M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.3M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +85.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.88M USD +34315%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.36M USD
Deferred Tax Assets, Operating Loss Carryforwards 123M USD -0.82%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.4M USD
Operating Lease, Payments 4.36M USD +773%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 42K USD -27.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%